Eva Gonzalez-Suarez

Eva Gonzalez-Suarez

UNVERIFIED PROFILE

Are you Eva Gonzalez-Suarez?   Register this Author

Register author
Eva Gonzalez-Suarez

Eva Gonzalez-Suarez

Publications by authors named "Eva Gonzalez-Suarez"

Are you Eva Gonzalez-Suarez?   Register this Author

41Publications

1645Reads

17Profile Views

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.

Oncogene 2019 11 13;38(45):7106-7112. Epub 2019 Aug 13.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0936-xDOI Listing
November 2019

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

Cancer Treat Rev 2019 Jun 15;76:57-67. Epub 2019 May 15.

Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Place A. Van Gehuchten 4, 1020 Brussels, Belgium.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372193006
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2019.05.003DOI Listing
June 2019

European Network of Breast Development and Cancer turned 10 years: a growing family of mammary gland researchers.

Breast Cancer Res 2018 09 4;20(1):102. Epub 2018 Sep 4.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199 - 203, L'Hospitalet deLlobregat, 08908, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1032-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122475PMC
September 2018

Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.

Cancer Cell 2018 06 24;33(6):1094-1110.e8. Epub 2018 May 24.

Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona 08028, Spain; ICREA, Pg. Lluís Companys 23, Barcelona 08010, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.04.010DOI Listing
June 2018

Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer.

Oncotarget 2017 Aug 29;8(31):51621-51629. Epub 2017 May 29.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18255DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584274PMC
August 2017

Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer.

Mol Cell Oncol 2017 28;4(4):e1338208. Epub 2017 Jun 28.

Transformation and Metastasis laboratory, Cancer Epigenetics and Biology Program (PEBC), Biomedical Research Institute of Bellvitge (IDIBELL), Barcelona, Spain, Av.Gran Via de L'Hospitalet, 199 - 203. L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2017.1338208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540214PMC
June 2017

RANKL inhibitors for osteosarcoma treatment: hope and caution.

Ann Transl Med 2016 Dec;4(24):534

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2016.12.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233523PMC
December 2016

RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.

Cancer Res 2016 10 1;76(19):5857-5869. Epub 2016 Aug 1.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2745DOI Listing
October 2016

Cancer network activity associated with therapeutic response and synergism.

Genome Med 2016 08 24;8(1):88. Epub 2016 Aug 24.

Breast Cancer and Systems Biology Lab, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Gran via 199, L'Hospitalet del Llobregat, Barcelona, 08908, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-016-0340-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995628PMC
August 2016

RANK as a therapeutic target in cancer.

FEBS J 2016 06 28;283(11):2018-33. Epub 2016 Jan 28.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/febs.13645DOI Listing
June 2016

Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation.

Stem Cells 2016 Apr 13;34(4):1027-39. Epub 2016 Jan 13.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.2271DOI Listing
April 2016

A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition.

Cancer Res 2014 Oct 8;74(19):5608-19. Epub 2014 Aug 8.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat; Barcelona, Spain. Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain. Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3659DOI Listing
October 2014

Targeting RANKL in metastasis.

Bonekey Rep 2014 9;3:519. Epub 2014 Apr 9.

Cancer Epigenetics and Biology Program PEBC, Bellvitge Institute for Biomedical Research, IDIBELL , Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bonekey.2014.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007167PMC
June 2014

Linkage of DNA methylation quantitative trait loci to human cancer risk.

Cell Rep 2014 Apr 3;7(2):331-338. Epub 2014 Apr 3.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain; Department of Physiological Sciences II, School of Medicine, University of Barcelona, 08036 Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2014.03.016DOI Listing
April 2014

Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.

Cancer Res 2013 Jul 17;73(14):4185-9. Epub 2013 May 17.

Cell Death Regulation Group, School of Medicine, University of Barcelona; and Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-0512DOI Listing
July 2013

Identification of NOG as a specific breast cancer bone metastasis-supporting gene.

J Biol Chem 2012 Jun 30;287(25):21346-55. Epub 2012 Apr 30.

Oncology Programme, Institute for Research in Biomedicine, IRB-Barcelona, 08028 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M112.355834DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375555PMC
June 2012

Evidence for a link between TNFRSF11A and risk of breast cancer.

Breast Cancer Res Treat 2011 Oct 4;129(3):947-54. Epub 2011 May 4.

Biomarkers and Susceptibility Unit, and Biomedical Research Center Network for Epidemiology and Public Health, Cancer Prevention and Control Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), Gran Via 199, L'Hospitalet, Barcelona 08908, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1546-7DOI Listing
October 2011

RANKL inhibition: a promising novel strategy for breast cancer treatment.

Clin Transl Oncol 2011 Apr;13(4):222-8

Transformation and metastasis group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-011-0646-5DOI Listing
April 2011

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.

Nature 2010 Nov 29;468(7320):103-7. Epub 2010 Sep 29.

Department of Hematology/Oncology Research, Amgen Inc, Seattle, Washington 98119, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature09495DOI Listing
November 2010

Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice.

Oncogene 2005 Mar;24(13):2256-70

Molecular Oncology Program, Spanish National Cancer Centre, E-28029 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1208413DOI Listing
March 2005

Telomere dysfunction results in enhanced organismal sensitivity to the alkylating agent N-methyl-N-nitrosourea.

Cancer Res 2003 Nov;63(21):7047-50

Department of Immunology and Oncology, National Center of Biotechnology, Madrid, Spain.

View Article

Download full-text PDF

Source
November 2003

Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development.

Mol Cell Biol 2002 Oct;22(20):7291-301

Department of Immunology and Oncology, National Center for Biotechnology, E-28049 Madrid, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC139804PMC
http://dx.doi.org/10.1128/mcb.22.20.7291-7301.2002DOI Listing
October 2002